In pre-market trading, shares of Theravance Biopharma (TBPH) are down 28% to $13.55 after the company announced that the Phase 3 CYPRESS study did not meet its primary endpoint. In addition, the board accelerated its strategic review and announced cost reduction actions.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma implements cost reduction actions after study results
- Theravance Biopharma Restructures After Ampreloxetine Trial Failure
- Theravance Biopharma trading resumes
- Theravance Biopharma says Phase 3 CYPRESS Study did not meet primary endpoint
- Theravance Biopharma winding down ampreloxetine program after Phase 3 results